No­var­tis con­sid­ers sell­ing its $5B+ oph­thal­mol­o­gy and res­pi­ra­to­ry units — re­port

As No­var­tis has been fo­cus­ing its core pipeline, and spin­ning off its gener­ics arm San­doz, the com­pa­ny may be look­ing to sell even more.

Ac­cord­ing to a re­port from Bloomberg to­day, the Swiss phar­ma is con­sid­er­ing the sale of some of its “non-core” as­sets to raise funds to in­vest in “cut­ting-edge med­i­cines,” peo­ple fa­mil­iar with the mat­ter said.

The re­port elab­o­rates that No­var­tis is in the ear­ly phas­es of “con­sid­er­ing op­tions” for its res­pi­ra­to­ry and oph­thal­mol­o­gy units, which wouldn’t close un­til af­ter San­doz spins out, with anony­mous sources telling the pub­li­ca­tion that pri­vate eq­ui­ty firms could spend up to $5 bil­lion on the oph­thal­mol­o­gy unit alone, ac­cord­ing to Bloomberg.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER